American Herbal Products Association (AHPA) > News > Alerts > Market Alerts

Market Alerts

November 2021

  • SCNM Dedicates Ric Scalzo Institute of Botanical Research
  • August 2021

    July 2021

    March 2021

    February 2021

    November 2020

    October 2020

    September 2020

    August 2020

    July 2020

    June 2020

    April 2020

    February 2020

    January 2020

  • Sabinsa's parent company Sami Labs breaks ground on $30 million state of the art production facility
  • Unstoppable Moms Across America launches new Gold Standard to shift the marketplace for a healthier planet
  • Draco Achieves Safe Quality Food (SQF) certification of its manufacturing facilities
  • August 2019

    June 2019

    May 2019

    March 2019

    February 2019

    January 2019

    December 2018

    November 2018

    October 2018

    September 2018

    August 2018

    July 2018

    May 2018

    April 2018

    March 2018

    February 2018

    January 2018

    December 2017

    November 2017

    October 2017

    September 2017

    August 2017

    July 2017

    June 2017

    FDA and FTC highlight attention to intravenous therapies and social media in COVID-19 warning letters

    Excerpt from the June 2020 AHPA Report

    Since the first week of March, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have been issuing warning letters alleging that marketers promoted a wide variety of products with claims to prevent, treat, mitigate, diagnose or cure COVID-19. AHPA has analyzed 135 COVID-19 related warning letters issued by either FDA or FTC or by the agencies jointly between March 6, 2020, and May 11, 2020, and made available in each agency’s coronavirus information center as of May 15, 2020.

    Free Webinar: Reopening Your Herbal Products Business -- COVID-19 & the “New Normal”

    Presented June 10, 2020

    This free webinar provides practical information on how best to resume post-quarantine business operations while protecting your workforce. Learn what personal protective equipment and workspace adaptations should be implemented and how to manage ongoing business risks and liabilities. Additionally, hear from experts about how to be proactive and search for, and then correct, workplace conditions that could increase risk of COVID-19 infections.

    Request for proposals: Slippery elm sustainable wild harvest study

    Request for proposals: Slippery elm sustainable wild harvest study

    Deadline extended to July 10, 2020

    The AHPA Foundation for Education and Research on Botanicals (AHPA ERB Foundation) is issuing a request for proposals to award grant funding to eligible applicants in order to enhance and promote knowledge and understanding of sustainable harvest of slippery elm (Ulmus rubra).  The grant supports research effects of varying rates of wild slippery elm bark harvest on tree population health and recovery across multiple harvest sites in order to inform sustainable harvest and management decisions for the species. The anticipated amount of funding available for a sustainable wild slippery elm bark harvest research project is up to $10,000 annually for up to 5 years.

    Webinar: Marketing Claims for Hemp-Derived Products

    Presented May 20, 2020 -- Duration: 2.5 hours

    This webinar provides guidance and practical tips on how to successfully market your hemp-derived products consistent with the requirements of the FDA and FTC. An FTC representative provides FTC’s perspective, summarizes recent enforcement actions, and discusses the level of substantiation respondents in those actions possessed or did not possess. Industry attorneys address legal standards, today’s ever-evolving regulatory environment, and the lawsuit risks and liabilities marketers of hemp products face.

    AHPA Hemp-CBD Status Report

    Updated in April 2020 to cover recent FDA and USDA actions • Log-in to download

    To help the herbal products industry understand the evolving regulatory landscape for hemp and hemp-derived cannabidiol (CBD) products, AHPA has updated its free Hemp-CBD Status Report to include recent actions taken by the Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA).

    Oregon adopts temporary rule prohibiting unsubstantiated claims that goods prevent, treat, diagnose, or mitigate COVID-19 related conditions

    April 17, 2020: AHPA has been working with other trade organizations to seek withdrawal of a much-broader proposed rule that the OR DOJ published for comment late last year and in amended form in March 2020.

    The Oregon Department of Justice (OR DOJ) has temporarily adopted a rule declaring it “unfair and deceptive” (and thus unlawful) to represent that any product “will prevent, treat, diagnose, mitigate, or cure coronavirus, COVID-19 or a related condition, without first having competent and reliable scientific evidence upon which to base a reasonable belief in the truth of the representation.” The temporary rule is effective for six months, until October 14, 2020.

    AHPA and CRN express concern about Proposed Rule in Oregon that would create private right of action for opportunistic plaintiffs’ lawyers

    April 2020: AHPA and CRN urge that Oregon Proposed Rule is unnecessary and should be withdrawn

    AHPA and the Council for Responsible Nutrition (CRN) filed joint comments last week to reiterate significant concerns to the Oregon Department of Justice (OR DOJ) about a Proposed Rule that would create a private right of action for opportunistic plaintiffs' lawyers motivated by the potential for recovery rather than the public interest.

    AHPA submits supply chain issues to USDA and continues to collect industry data

    April 10, 2020: Report your supply chain issues to AHPA using this brief survey

    AHPA has reported to the U.S. Department of Agriculture (USDA) a host of supply chain issues submitted by members and others in the herbal community. The information submitted to USDA reports on shortages or delivery disruptions of a variety of ingredients, supplies, and services. AHPA also continues to collect supply chain data to inform the industry, regulators and lawmakers.

    Supplement Industry Associations Applaud FDA Actions to Protect Consumers from Fraudulent Products Related to Coronavirus Disease (COVID-19)

    Washington D.C., April 6, 2020

    The U.S. dietary supplement industry commends the Food and Drug Administration (FDA) for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. In February, the industry issued strong warning to companies and consumers to avoid marketing or using dietary supplements that are presented as treating, curing or preventing COVID-19.

    IADSA update on international supplement regulations

    IADSA update on international supplement regulations

    April 2020 IADSA Newsflash

    This issue of the IADSA Newsflash covers the European Commission's draft regulation directed at botanicals containing hydroxyanthracene derivatives (HADs), Belgium recently published guidance on the analysis for four new plants, Ireland survey of cannabidiol (CBD) products that found a majority were not in compliance with various regulations, Norway's risk assessment of caffeine and more.

    RSS
    12345678910 Last

    2021 Annual Fund Sponsors

        

    AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.